Healthcare
Live Price
Offline$44.75
-0.58% today
1Y Change
-21.96%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 251 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zealand Pharma A/S (ZLDPF) is a Healthcare stock with a market cap of $21.11B and listed on OTC. The stock last traded around $44.75 and down 22.0% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +14565.6%, EPS growth of +662.7%, a dividend yield of 0.0%. What stands out right now is revenue +14565.6%, EPS +662.7%, free cash flow +786.9% with operating margin 75.5% and ROIC 40.6%. Valuation is more restrained than many high-expectation growth names at P/E 3.3 and price/sales 2.3. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines ZLDPF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZLDPF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ZLDPF Max Drawdown
-53.14%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ZLDPF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$292.6M
+181.4% YoY
FY Net Income
-$1.0B
-5.4% YoY
Free Cash Flow
-$1.2B
-29.4% YoY
Revenue Growth
+14565.6%
EPS Growth
+662.7%
Gross Margin
99.8%
Net Margin
70.0%
Income statement
DKK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 9.2B | 63M | 343M | 104M | 293M |
| Gross Profit | 9.2B | 55M | 324M | 73M | 174M |
| Operating Income | 7.1B | -1.3B | -572M | -817M | -1.1B |
| EBITDA | 7.2B | -1.0B | -658M | -665M | -712M |
| Net Income | 6.4B | -1.1B | -704M | -966M | -1.0B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
DKK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4.6B | 480M | 449M | 1.1B | 1.1B |
| Total Assets | 16.4B | 9.5B | 2.0B | 1.5B | 2.1B |
| Total Liabilities | 1.6B | 889M | 387M | 724M | 1.1B |
| Shareholder Equity | 14.8B | 8.6B | 1.6B | 816M | 928M |
| Total Debt | 485M | 392M | 119M | 443M | 787M |
| Net Debt | -4.1B | -89M | -330M | -626M | -342M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1.2B
-28.6% YoY
Capital Expenditures
22M
-89.0% YoY
Free Cash Flow
1.2B
-29.4% YoY
Key ratios
Gross Margin
99.8%
Operating Margin
75.5%
Net Margin
70.0%
ROE
47.9%
Debt / Equity
0.03x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.